Terms: = Prostate cancer AND COL2A1, SEDC, MGC131516, COL11A3, AOM, ANFH, ENSG00000139219, 1280 AND Treatment
10 results:
1. Findings on Diagnostic Magnetic Resonance Imaging Before Radiotherapy for prostate cancer.
Dahan J; Delouya G; Lambert C; Olivié DAR; Billiard JS; Taussky D
Can Assoc Radiol J; 2023 May; 74(2):382-387. PubMed ID: 36325740
[TBL] [Abstract] [Full Text] [Related]
2. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R;
Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
[TBL] [Abstract] [Full Text] [Related]
4. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract] [Full Text] [Related]
5. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract] [Full Text] [Related]
6. Potent anti-cancer effects of citrus peel flavonoids in human prostate xenograft tumors.
Lai CS; Li S; Miyauchi Y; Suzawa M; Ho CT; Pan MH
Food Funct; 2013 Jun; 4(6):944-9. PubMed ID: 23673480
[TBL] [Abstract] [Full Text] [Related]
7. Effectiveness of using fewer implanted fiducial markers for prostate target alignment.
Kudchadker RJ; Lee AK; Yu ZH; Johnson JL; Zhang L; Zhang Y; Amos RA; Nakanishi H; Ochiai A; Dong L
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1283-9. PubMed ID: 19427750
[TBL] [Abstract] [Full Text] [Related]
8. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Slovin SF; Ragupathi G; Fernandez C; Diani M; Jefferson MP; Wilton A; Kelly WK; Morris M; Solit D; Clausen H; Livingston P; Scher HI
Cancer Immunol Immunother; 2007 Dec; 56(12):1921-30. PubMed ID: 17619878
[TBL] [Abstract] [Full Text] [Related]
9. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
Urologiia; 2001; (4):26-9. PubMed ID: 11569230
[TBL] [Abstract] [Full Text] [Related]
10. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
[TBL] [Abstract] [Full Text] [Related]
